On December 3, 2023, Prof. Paras N. Prasad from the State University of New York, USA, visited the International Research Center for Advanced Photonics at Zhejiang University, Haining International Campus. Guided by Prof. Jun Qian, Prof. Prasad embarked on an insightful tour of the center's laboratories, with a particular focus on the biophotonics lab. Following the visit, Prof. Prasad engaged in a profound discussion and exchange of ideas with the center's researchers, delving into the advancements in Biomedical Optics and exploring avenues for future collaborative research.
Prof. Paras N. Prasad holds a distinguished multidisciplinary position as SUNY Distinguished Professor, spanning across Chemistry, Physics, Electrical Engineering, and Medicine at the State University of New York. As the Samuel P. Capen Chair of Chemistry and the founding Executive Director of the Institute for Lasers, Photonics and Biophotonics since 1999, his contributions to the scientific community have been monumental. Recognized as one of the top 50 science and technology leaders by Scientific American, he has an impressive portfolio of around 900 scientific papers, four groundbreaking monographs, eight edited volumes, and a plethora of patents. His pioneering work in organic nonlinear optics, nanophotonics, biophotonics, and nanomedicine has marked significant milestones in these fields. With an H-Index of 136 and about 84,000 citations on Google Scholar, his impact on the scientific world is undeniable.
Prof. Prasad's accolades extend to being an elected foreign fellow of the National Academy of Sciences, India, and the Brazilian Academy of Sciences. He is a fellow of the National Academy of Inventors, as well as of the APS, OSA, SPIE, and IEEE. His global influence is further highlighted by his honorary doctorates from prestigious institutions like KTH in Sweden, Aix-Marseille University in France, MEPhI in Russia, and the Federal University of Pernambuco in Brazil. He has received an honorary professorship from Zhejiang University in 2006. Globally, his technologies have produced 9 spin-off companies, including publicly-traded Nanobiotix, now in advanced clinical trials for cancer therapy.
